The Company will demonstrate the effectiveness of IkT-001Pro against patient-derived JCV isolated from the urine of patients chronically infected with virus, the first time a direct measure of antiviral potency against patient-derived virus has been possible.
http://www.biospace.com/news_story.aspx?StoryID=294349&full=1
http://www.biospace.com/news_story.aspx?StoryID=294349&full=1
